It has been reported that tepotinib, a potent c-Met inhibitor, exhibits promising activity in advanced HCC with c-Met overexpression in clinical studies, indicating that c-Met may serve as a therapeutic target for HCC [5]. This evidence concerns the gene MET and hepatocellular carcinoma.